# OnCo record allogene (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/allogene/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "allogene" ;
  schema:name "Allogene Therapeutics"@en ;
  schema:description "Allogeneic CAR-T leader: cema-cel (CD19) as MRD-guided first-line consolidation in lymphoma, and ALLO-316 (CD70) with responses in kidney cancer."@en ;
  schema:url <https://onco.cc/companies/allogene/>, <https://allogene.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-receives-fda-regenerative-medicine-0> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/rcc/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd70/> ;
  onco:drugs <https://onco.cc/drugs/allo-647/> ;
  onco:terms <https://onco.cc/terms/mrd/> ;
  onco:trials <https://onco.cc/trials/nct04416984/>, <https://onco.cc/trials/nct06500273/> .